Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Abu-Khalaf

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 22, 2014
Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancerCarlos Acevedo-Gadea, Alessandro D Santin, Susan A Higgins, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 17, 2024
Coverage for evidence-based cancer survivorship care servicesAnne H Blaes, Maysa M Abu-Khalaf, Catherine M Bender, et al.
Cancer|April 24, 2015
Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United StatesSarah S Mougalian, Pamela R Soulos, Brigid K Killelea, et al.
European Journal of Gynaecological Oncology|May 14, 2016
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcomaM M Abu-Khalaf, M A Raza, C Hatzis, et al.
Breast Cancer Research and Treatment|October 20, 2006
Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancerMaysa M Abu-Khalaf, Vinni Juneja, Gina G Chung, et al.
Journal of Oncology Practice|March 19, 2015
Systematic approach to providing breast cancer survivors with survivorship care plans: a feasibility studyKaleigh J Bulloch, Melinda L Irwin, Anees B Chagpar, et al.
British Journal of Cancer|April 26, 2012
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapyS Bellone, D Roque, E Cocco, et al.
NPJ Breast Cancer|June 2, 2021
Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancerRui Luo, Weelic Chong, Qiang Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast CancerVinay Varadan, Hannah Gilmore, Kristy L S Miskimen, et al.
Oncology|December 2, 2005
Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancerMaysa M Abu-Khalaf, Stephen Windsor, Keita Ebisu, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 22, 2014
Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancerCarlos Acevedo-Gadea, Alessandro D Santin, Susan A Higgins, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 17, 2024
Coverage for evidence-based cancer survivorship care servicesAnne H Blaes, Maysa M Abu-Khalaf, Catherine M Bender, et al.
Cancer|April 24, 2015
Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United StatesSarah S Mougalian, Pamela R Soulos, Brigid K Killelea, et al.
European Journal of Gynaecological Oncology|May 14, 2016
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcomaM M Abu-Khalaf, M A Raza, C Hatzis, et al.
Breast Cancer Research and Treatment|October 20, 2006
Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancerMaysa M Abu-Khalaf, Vinni Juneja, Gina G Chung, et al.
Journal of Oncology Practice|March 19, 2015
Systematic approach to providing breast cancer survivors with survivorship care plans: a feasibility studyKaleigh J Bulloch, Melinda L Irwin, Anees B Chagpar, et al.
British Journal of Cancer|April 26, 2012
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapyS Bellone, D Roque, E Cocco, et al.
NPJ Breast Cancer|June 2, 2021
Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancerRui Luo, Weelic Chong, Qiang Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast CancerVinay Varadan, Hannah Gilmore, Kristy L S Miskimen, et al.
Oncology|December 2, 2005
Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancerMaysa M Abu-Khalaf, Stephen Windsor, Keita Ebisu, et al.
Pageof 5